Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial

The goal of this clinical trial is to :
1. Test whether the combination of CAZ?AVI and FOS leads to superior clinical outcomes in patients with severe suspected Gram-negative bacterial infection, as demonstrated by a shorter time to normalization of quick Sequential Organ Failure Assessment (qSOFA) parameters and reduction in C-reactive protein (CRP) compared to standard of care (CAZ?AVI alone)
2. to further characterize the safety profile of this combination therapy
In the presence of such an infection, standard treatment is to start intravenous antibiotic therapy. Ceftazidime (Fortam?), or ceftazidime-avibactam (Zavicefta?), is a standard antibiotic commonly used for this purpose (for very resistant bacteria, the compound avibactam is included to protect ceftazidime from being broken down by bacteria).
Researchers will compare ceftazidime (or ceftazdime-avibactam) plus fosfomycin versus ceftazidime alone with placebo (i.e. a look-alike substance given with no drug) to examine whether the addition of another intravenous antibiotic, fosfomycin, would lead to faster recovery from severe infection and evaluate the tolerability of this combination.
Participants will:
* Be randomly assigned to either the intervention group or the control group.
* The intervention group will receive ceftazidime (with avibactam if multidrug resistant bacteria are suspected, per routine practice) and intravenous fosfomycin, and the control group will receive ceftazidime (with avibactam if multidrug resistant bacteria are suspected) and placebo.
* Either treatment will be given for 3 days, three times daily (or less frequently, depending on renal function).
* Provide a few extra blood samples (for CRP measurement, a protein marker of inflammation) during the first few days of the study.
* Be contacted in the hospital or by phone if discharged on day 28 to be asked a few questions.

开始日期2025-07-01

申办/合作机构

University of Geneva

[+1]

NCT07016165

/ Not yet recruiting临床4期IIT

Ciprofloxacin Versus Ceftazidime as Empirical Therapy of High-Risk Neutropenic Fever in Children With Hematologic Malignancies : A Randomized Controlled Trial

This clinical trial will compare use of ciprofloxacin and ceftazidime work in treating high-risk fever in children with hematological malignancies
1. Does ceftazidime work better than ciprofloxacin as a first-choice antibiotic for children with hematological malignancies who have high-risk fever from low neutrophil count?
2. Are there any specific factors that affect how children with hematological malignancies respond to ciprofloxacin or ceftazidime when treating high-risk fever?
Participants in this study are children with hematological malignancies who have a high risk of fever due to low neutrophil count. Children, aged 0 to 18 years old, will be hospitalized between June and December 2025 at Sardjito General Hospital
The study will involve:
* Collecting patient history, conducting physical exams, and performing supporting tests.
* Randomly assigning participants into two groups: one group will receive the standard treatment with intravenous ciprofloxacin, while the other group will receive the intervention treatment with intravenous ceftazidime.
* Both groups will be monitored for various outcomes, including the length of fever, length of low white blood cell count, length of hospital stay, length of antibiotic use, any changes in antibiotics, and mortality.

开始日期2025-06-15

申办/合作机构

Universitas Gadjah Mada

NCT06406114

/ Recruiting临床2期IIT

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

开始日期2025-05-05

申办/合作机构

The General Hospital Corp.

[+1]

100 项与头孢他啶相关的临床结果

登录后查看更多信息

100 项与头孢他啶相关的转化医学

登录后查看更多信息

100 项与头孢他啶相关的专利（医药）

登录后查看更多信息

40,915

项与头孢他啶相关的文献（医药）

2025-12-31·Sustainable Environment

A review on the occurrence of antibiotic-resistant bacteria found in abattoir effluent from resource-limited settings: The necessity of a robust One Health framework

作者: Dinginya, Lawrance ; Jambwa, Prosper ; Majuru, Chenai Sipiwe ; Chari, Tawanda Ashley ; Machakwa, Jairus ; Mahlangu, Precious ; Gufe, Claudious ; Marowero, Sheunesu Theo ; Kadungure, Tafadzwa

A review.Abattoirs discharge untreated waste into surrounding bodies of water and the environment, which is extremely harmful to public health.Bacteria that cause disease, especially those resistant to antibiotics, may be present in these wastes.This review was carried out to provide a comprehensive overview of antibiotic-resistant microbes discovered in slaughterhouse wastes in resource-limited settings.Relevant research studies focussing on bacteria isolated from abattoir effluents in resource-limited settings and AMR patterns were searched on Google Scholar, PubMed, Web of Science, and African journals online.The studies showed that numerous bacteria were detected, such as Salmonella spp., Bacillus spp.,Shigella spp.,Escherichia coli, Pseudomonas aeruginosa, Citrobacter freundii, Proteus spp.,Streptococcus spp.,Yersinia spp. and Staphylococcus aureus.Several of these isolates were resistant to multiple antibiotics, including Penicillin, Vancomycin, Clindamycin, Erythromycin, Tetracycline, Ampicillin, Linezolid, Gentamycin, Ciprofloxacin, Ampicillin, Ceftriaxone, Imipenem, Cefotaxime, Chloramphenicol, Trimethoprim-sulfamethoxazole, Piperacillin-Tazobactam, Ceftazidime, Imipenem, and Meropenem.Lack of proper waste management practices due to financial constraints is the major cause of a high prevalence of resistant bacterial strains in abattoir effluents in resource-limited settings.Given the critical role that the environment plays in the spread and maintenance of antibiotic-resistant microorganisms, public health systems must strengthen One Health National Action plans applicable to abattoir effluents to successfully combat antibiotic resistance.

2025-12-31·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

作者: de Gunzburg, Jean ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India

Article

作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay

BACKGROUND:

Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.

METHODS AND RESULTS:

Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase bla_NDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.

CONCLUSIONS:

This is the first report of carbapenem-resistant Escherichia coli carrying bla_NDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.

234

项与头孢他啶相关的新闻（医药）

2025-07-04

·赛柏蓝

集采八年，大品种还剩多少？

特约作者 | 张自然博士责任编辑 | 郑瑶集采旨在挤水分，所以纳入集采的都是大品种。集采已进入第八年，大品种状况如何？本文就国采前（2018年）后（2024年）年销售额超30亿元的化学仿制药大品种数量、规模、结构变化情况做一分析。注：①本文中的大品种特指在医院销售的、年销售额超30亿元的化学仿制药（通用名）；②本文中的“集采前”特指2018年，“集采后”特指2024年。01整体一、大品种数量：腰斩集采八年，大品种数量已减少过半（56%），由集采前（2018年）的27个减少到了集采后（2024年）的12个。（详见图一）二、整体规模：下降6成集采前，大品种（27个）年销售合计超千亿（1289亿元），集采后，大品种（12个）年销售合计只有482亿元，减少了807亿元，八年下降了近2/3（63%）。（详见图一）三、单品规模：锐减集采前，最大品种过百亿，如硫酸氢氯吡格雷片103亿元、阿托伐他汀钙片100亿元。集采后，最大品种（注射用头孢哌酮钠舒巴坦钠）仅65亿元，比集采前的最大品种小了近4成（37%），比集采前位居第3位的地佐辛注射液（66亿元）的体量还小。（详见图一）02解析一、集采前的大品种：近八成已跌出30亿阵营集采前（2018年）的27个大品种中，在集采后（2024年）有21个已跌出30亿阵营，占集采前大品种总数的近八成（78%）。集采前的27个大品种中，已被纳入国采的也是21个，即近八成（78%）已被国采。1、已国采：21个（近八成）如图二所示，纳入大品种数最多的是第一、五两批国采，都纳入了6个大品种，第一批以口服为主，都是规模超大的品种，第五批都是注射剂。如第一批的硫酸氢氯吡格雷片、阿托伐他汀钙片、注射用培美曲塞二钠、瑞舒伐他汀钙片、苯磺酸氨氯地平片、恩替卡韦分散片；纳入第五批国采的是吸入用布地奈德混悬液、多西他赛注射液、注射用头孢他啶、注射用兰索拉唑、碘克沙醇注射液、注射用艾司奥美拉唑钠；第七批有3个，也都是注射剂，即注射用美罗培南、注射用奥美拉唑钠、依达拉奉注射液；第二、八两批都纳入了2个大品种，第二批的都是口服，即阿卡波糖片、替吉奥胶囊；第八批的都是注射剂，即注射用头孢哌酮钠舒巴坦钠、注射用哌拉西林钠他唑巴坦钠；第三、四批各纳入1个，分别是卡培他滨片、注射用泮托拉唑钠；第九、十批国采已不再有30亿元以上的大品种了。上述21个纳入国采的大品种，有7成（15个）在集采后（2024年）跌出了30亿阵营，只有6个（29%）年销售仍超30亿，其中，除注射用头孢哌酮钠舒巴坦钠⑧销售增长了5%外，其余5个（硫酸氢氯吡格雷片①、阿托伐他汀钙片①、注射用美罗培南⑦、吸入用布地奈德混悬液⑤、注射用哌拉西林钠他唑巴坦钠⑧）的年销售额均大幅下降，分别较集采前（2018年）下降了61%、57%、46%、33%、32%。（详见图二）注：上述品名后带括号的数字表示国采批次（下同）2、未国采：6个（约1/5）如图二所示，集采前的27个大品种中，有6个未被国采（约占1/5），包括4个重点监控品种（单唾液酸四己糖神经节苷脂钠注射液、注射用磷酸肌酸钠、前列地尔注射液、脑苷肌肽注射液）、1个独家品种（地佐辛注射液），以及注射用亚胺培南西司他丁钠。后者也已被纳入网传的第11批拟国采品种清单。二、集采后的大品种如图二所示，集采后（2024年）的大品种共有12个，其中，一半是集采前（2018年）就在大品种之列的（如上文所述），一半是集采后的几年内才成长为大品种的。在新增的6个大品种中，有2个复杂制剂（注射用醋酸亮丙瑞林微球、盐酸多柔比星脂质体注射液⑩），1个麻醉剂（注射用盐酸瑞芬太尼）、1个造影剂（碘佛醇注射液⑤），和2个普通制剂（他克莫司胶囊、依西美坦片）。集采减少了大品种数量，改变了大品种结构。同质化太强的仿制药，因竞争已足够充分而被集采。复杂制剂、麻醉药等小众品种尚可残存更长些时间。注：欢迎转载！但在转载或引用本文图片时，除公众号外，还请标明作者。谢谢！END内容沟通：郑瑶（13810174402）

带量采购

2025-06-19

·米内网

【瞩目】超15亿抗细菌药，石药过评了

精彩内容日前，国家药监局官网显示，石药集团中诺药业（石家庄）的注射用苯唑西林钠一致性评价补充申请获批。米内网数据显示，注射用苯唑西林钠在2024年中国公立医疗机构终端销售额超过15亿元。截至目前，石药集团在全身用抗细菌化药领域已有43款产品通过/视同通过一致性评价。注射用苯唑西林钠用于治疗产青霉素酶葡萄球菌感染，包括败血症、心内膜炎、肺炎和皮肤、软组织感染等，也可用于化脓性链球菌或肺炎球菌与耐青霉素葡萄球菌所致的混合感染。近年中国公立医疗机构终端注射用苯唑西林钠销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局注射用苯唑西林钠在2024年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额超过15亿元，是全身用抗细菌化药TOP15产品。米内网数据显示，注射用苯唑西林钠有25家企业拥有生产批文，石药集团中诺药业（石家庄）、福安药业庆余堂制药、山东道齐生物医药等13家企业过评，华北制药、悦康药业等4家的一致性评价补充申请在审，山东鲁抗医药、江苏江丰医药等10家企业均以仿制3类报产在审，获批后视同过评。石药集团今年此前全身用抗细菌化药过评情况来源：米内网一致性评价进度数据库今年以来，石药集团在全身用抗细菌化药领域已有6款产品通过/视同通过一致性评价，其中，注射用头孢唑肟钠、注射用头孢他啶在2024年中国公立医疗机构终端分别是40亿元、20亿元大品种。截至目前，石药集团在全身用抗细菌化药领域已有43款产品通过/视同通过一致性评价。资料来源：国家药监局官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

2025-06-18

·米内网

科伦药业厉害了！拿下35个重磅品种，26款1类新药、74个新品出击，198个过评品种霸屏

精彩内容近段时间，科伦药业产品管线进展频频：1类新药注射用SKB315新适应症获批临床、注射用头孢唑林钠/氯化钠注射液国内第2家获批等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，2024年研发投入21.71亿元（+11.2%），目前有42款新药（26款1类新药）处于申报临床及以上阶段；仿制药方面，累计有198个品种过评（50余个首家/独家），74个新品瞄准160亿市场。拿下35个品种！198个过评品种霸屏近日，科伦药业2款3类仿制药获批生产并视同过评，为注射用头孢唑林钠/氯化钠注射液、注射用青霉素钠，均属于全身用抗感染药物。其中，注射用头孢唑林钠/氯化钠注射液国内第2家获批，同时也是公司粉液双室袋平台第11个获批的产品。今年以来，科伦药业（含子公司及联营公司，下同）产品管线持续推进。在新注册分类品种审评方面，科伦药业有35个品种获批生产并视同过评，领跑国内其他药企。2025年以来科伦药业获批上市的仿制药来源：米内网中国申报进度（MED）数据库35个品种中，有多个品种为国内首批上市，其中芦曲泊帕片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液等为国内首仿+首家过评，阿帕他胺片、枸橼酸钠血滤置换液、注射用头孢他啶/氯化钠注射液等为国产第2家获批，复方氨基酸注射液(18AA-Ⅸ)、他克莫司缓释胶囊、昂丹司琼口溶膜、复方电解质醋酸钠注射液等为国产第3家获批等。截至目前，科伦药业已有198个品种通过/视同通过一致性评价，在过评品种数TOP10集团中排位第二。其中，50余个品种为国内首家过评，包括芦曲泊帕片、氢溴酸替格列汀片、琥珀酸曲格列汀片、泊沙康唑口服混悬液、注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等18个独家过评品种。在国家开展的九批十轮化药集采中，科伦药业分别有1个、5个、4个、4个、11个、11个、7个、4个、12个品种成功中选，合计59个品种。集采常态化推进背景下，科伦药业恰逢产品线密集收获期，并积极参与集采，目前已成为集采头部供应商之一。在第十一批集采中，预计科伦药业将仍旧为“主力军”，目前已有近40个品种达到入围门槛，注射剂占“半壁江山”。其中，有10余个为2025年后新获批品种，包括罗沙司他胶囊、注射用头孢他啶阿维巴坦钠(4:1)等临床畅销品种。26款1类新药出击，猛攻2300亿市场今年以来，科伦药业国内新药研发进展不断：生物类似药西妥昔单抗注射液获批上市，为国产首家；PD-L1单抗塔戈利单抗注射液、TROP2 ADC注射用芦康沙妥珠单抗获批新适应症；1类新药注射用SKB445、SKB107注射液，以及2.2类改良型新药KLA480注射液、注射用KLA578-1、KLA514-2片、A140注射液等均首次获批临床。国际化方面，新型ADC药物SKB518在美获批临床，用于治疗晚期实体瘤，该药已在国内开展II期临床试验；以不超过9.7亿美元的首付款和里程碑付款，将TSLP单抗SKB378/HBM93781在全球范围内（不包括大中华区以及部分东南亚及西亚国家）的研发、生产和商业化的独家授权给Windward Bio等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，不断加大研发投入支持创新发展。2023年公司研发投入19.5亿元，同比增长7.59%；2024年进一步增长至21.71亿元，同比增长11.2%。近年来科伦药业研发投入情况（单位：亿元）来源：公司公告，米内网整理目前科伦药业有42款新药在国内处于申报临床及以上阶段，涉及26款1类新药、15款2类改良型新药、1款生物类似药，聚焦肿瘤、精神神经、心血管、肝病、呼吸等疾病领域，其中抗肿瘤药独占“半壁江山”。米内网数据显示，2024年中国三大终端六大市场抗肿瘤和免疫调节剂（化学药+生物药）销售额超过2300亿元。科伦药业国内在研新药来源：米内网综合数据库42款新药中，1类新药注射用博度曲妥珠单抗、制剂改良型新药布瑞哌唑口溶膜已申报NDA，上市可期。博度曲妥珠单抗为靶向HER2的ADC药物，全球已获批上市的同靶点同类型药物中，罗氏的恩美曲妥珠单抗、第一药品/阿斯利康的德曲妥珠单抗2024年全球销售额分别达19.98亿瑞士法郎、5.45亿美元。口溶膜制剂方面，昂丹司琼口溶膜已顺利获批，布瑞哌唑口溶膜、枸橼酸西地那非口溶膜2款产品报产在审，盐酸达泊西汀口溶膜、盐酸鲁拉西酮口溶膜等获批临床，提升了公司复杂制剂领域产线价值。在研1类新药中，ADC药物是科伦药业重点布局的药物形式之一，目前已有芦康沙妥珠单抗（TROP2 ADC）1款新药获批上市，此外还有9款ADC药物处于获批临床及以上阶段，其中新型双抗ADC药物SKB571，以及SKB518、MK-6204、SKB445等具有潜在FIC靶点的新型ADC药物等均处于I期临床。目前全球已有10多款ADC药物获批上市，2024年全球销售额合计约130亿美元。74个新品瞄准160亿市场！29个品种抢首仿仿制药申报方面，目前科伦药业还有74个新注册分类品种在审（不含已有批文、主动撤回品种），形成了梯度丰富的研发管线，主要集中在血液和造血系统药物（16个）、神经系统药物（15个）、全身用抗感染药物（8个）、消化系统及代谢药（7个）等。74个品种2024年在中国三大终端六大市场的销售额合计超过160亿元。其中，低钙腹膜透析液(乳酸盐-G1.5%)、艾拉莫德片均超过10亿元，低钙腹膜透析液(乳酸盐-G2.5%)、丙戊酸钠缓释片(Ⅰ)均超过9亿元，双氯芬酸二乙胺乳胶剂、磷酸芦可替尼片均超过8亿元。29个品种暂无首仿（含剂型首仿）获批上市，包括注射用头孢噻肟钠/氯化钠注射液、注射用盐酸头孢替安/氯化钠注射液、雌二醇地屈孕酮片、佩玛贝特片、苯磺酸氨氯地平口服溶液、甲磺酸沙非胺片、苹果酸奈诺沙星氯化钠注射液、注射用头孢唑肟钠/氯化钠注射液、右美沙芬安非他酮缓释片、注射用阿立哌唑、枸橼酸西地那非口溶膜、布瑞哌唑片、罗替高汀贴片、奈妥匹坦帕洛诺司琼胶囊、西尼莫德片、奥贝胆酸片等。科伦药业新分类申报在审且暂无首仿获批的品种来源：米内网中国申报进度（MED）数据库此外，注射用头孢哌酮钠舒巴坦钠氯化钠注射液、伊布替尼片、双氯芬酸钠贴片、瑞舒伐他汀依折麦布片(Ⅰ)、屈螺酮炔雌醇片、磷酸芦可替尼片、结构脂肪乳注射液(C6-24)、腹膜透析液(碳酸氢盐-G4.25%)、复方聚乙二醇电解质散(Ⅱ)、恩他卡朋双多巴片(Ⅱ)、布立西坦片、吡仑帕奈口服混悬液、10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液等品种获批国产企业数均只有1家。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月16日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准生物类似药

100 项与头孢他啶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07654	头孢他啶	J01DD02	DB00438

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	中国	东北制药集团股份有限公司	1993-01-01
附件炎	日本	GlaxoSmithKline KK	1986-08-01
细菌性心内膜炎	日本	GlaxoSmithKline KK	1986-08-01
出血性败血症	日本	GlaxoSmithKline KK	1986-08-01
肺脓肿	日本	GlaxoSmithKline KK	1986-08-01
脑膜炎	日本	GlaxoSmithKline KK	1986-08-01
中耳炎	日本	GlaxoSmithKline KK	1986-08-01
咽喉炎	日本	GlaxoSmithKline KK	1986-08-01
肺炎	日本	GlaxoSmithKline KK	1986-08-01
前列腺炎	日本	GlaxoSmithKline KK	1986-08-01
肾盂肾炎	日本	GlaxoSmithKline KK	1986-08-01
继发感染	日本	GlaxoSmithKline KK	1986-08-01
鼻窦炎	日本	GlaxoSmithKline KK	1986-08-01
扁桃体炎	日本	GlaxoSmithKline KK	1986-08-01
骨和关节感染	美国	PAI Holdings LLC	1985-07-19
中枢神经系统感染	美国	PAI Holdings LLC	1985-07-19
妇科感染	美国	PAI Holdings LLC	1985-07-19
腹腔感染	美国	PAI Holdings LLC	1985-07-19
下呼吸道感染	美国	PAI Holdings LLC	1985-07-19
脓毒症	美国	PAI Holdings LLC	1985-07-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2022	N/A	-	-	IP Ceftazidime	齋襯繭願醖襯獵夢製範(簾觸遞鑰餘淵膚構窪積) = This first reported case of antibiomania with IP ceftazidime highlights the importance of recognizing psychiatric side effects of antibiotics which, if left untreated can have devastating effects on patient care and quality of life. 願鹽獵鑰廠餘醖醖網壓 (糧壓築衊鬱衊獵壓襯鹹 )	-	2022-11-04
				Divalproex Sodium
SOHO2022	N/A	中性粒细胞减少	-	AML-332 (Klebsiella pneumonia)	鑰積願憲觸淵淵顧夢選(膚範餘鑰蓋構艱夢膚製) = 鹹艱淵憲糧築醖憲簾憲餘齋觸鹹繭顧鹹選糧願 (選簾觸鏇衊鏇獵醖網網 ) 更多	-	2022-10-01
				AML-332 (Acinetobacter baumannii)	鑰積願憲觸淵淵顧夢選(膚範餘鑰蓋構艱夢膚製) = 廠築製積艱繭糧獵廠鹹餘齋觸鹹繭顧鹹選糧願 (選簾觸鏇衊鏇獵醖網網 ) 更多
NCT02787057 (PD, CTgov)	N/A	腹膜透析相关性腹膜炎	80	ceftazidime+Vancomycin (Control Group)	壓顧衊選蓋獵憲顧衊醖 = 繭鹹選夢簾築顧簾醖淵壓鹹鹹壓衊糧齋築鬱觸 (鹹構觸顧遞衊淵窪鬱網, 醖襯衊淵積鹽齋繭鏇憲 ~ 顧選積簾獵鏇顧獵蓋構) 更多	-	2020-03-26
				moxifloxacin+Vancomycin (Study Group)	壓顧衊選蓋獵憲顧衊醖 = 繭繭襯衊觸淵範獵壓鹹壓鹹鹹壓衊糧齋築鬱觸 (鹹構觸顧遞衊淵窪鬱網, 壓構艱壓選獵範齋繭製 ~ 夢壓築夢簾糧齋憲窪齋) 更多
ARVO2016	N/A	眼内炎一线	588	Amikacin	網積淵鹽願鑰淵網積憲(餘簾鬱淵構憲獵選醖繭) = may be a concern 積鏇醖壓繭夢鏇壓艱鏇 (簾鹽鬱願糧鑰窪糧鬱憲 )	积极	2016-05-01
SHIFT (ASN2015)	N/A	危重病	-	Ceftazidime 2g q12h	憲選鹹構蓋憲憲觸遞壓(構網蓋鏇繭築遞築襯鬱) = 蓋製廠糧積願構構膚襯網觸範餘製願餘鬱鑰壓 (願壓夢獵獵夢壓願遞積 )	积极	2015-11-03
				Ceftazidime 1g q6h	憲選鹹構蓋憲憲觸遞壓(構網蓋鏇繭築遞築襯鬱) = 選積餘齋醖壓鑰鹽簾憲網觸範餘製願餘鬱鑰壓 (願壓夢獵獵夢壓願遞積 )
ASN2014	N/A	-	36	Cefazolin (CZL) alone	遞壓醖窪築選簾簾膚廠(襯顧窪願選構齋餘衊廠) = 廠糧夢範鏇醖繭範鏇範壓廠築觸簾鬱餘蓋夢顧 (獵獵鬱淵糧鹽顧淵遞簾 )	积极	2014-11-11
				Ceftazidime (CTD) alone	觸顧觸餘憲選積簾廠鬱(選顧鏇觸鏇繭獵餘網糧) = 艱夢鹹淵鹽顧願構願膚鬱鹹網積鑰壓觸窪齋夢 (積夢廠網膚築壓襯觸願 )
Pubmed \| Perit Dial Int	N/A	腹膜炎	10	Ceftazidime	醖壓願淵鬱製鹹蓋夢選(憲鏇積範觸遞壓憲製壓) = 簾蓋廠繭艱蓋醖窪鏇鏇襯夢顧鏇衊齋淵蓋襯鏇 (製廠願構餘糧鑰夢衊襯 )	积极	2003-11-01
Pubmed \| Am J Kidney Dis	N/A	一线	10	ceftazidime	鏇鏇鑰鑰壓廠窪衊範網(網積範糧顧遞憲鏇繭襯) = 艱選齋繭築鬱鑰鹹網齋觸餘膚餘膚壓觸醖網網 (網餘鏇鹹憲範願顧簾製, 14) 更多	-	1999-01-01
				ceftazidime	鏇鏇鑰鑰壓廠窪衊範網(網積範糧顧遞憲鏇繭襯) = 艱觸憲鹽衊鬱艱遞構蓋觸餘膚餘膚壓觸醖網網 (網餘鏇鹹憲範願顧簾製, 14) 更多